Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

被引:220
作者
Walsh, MJ
Jonsson, JR
Richardson, MM
Lipka, GM
Purdie, DM
Clouston, D
Powell, EE
机构
[1] Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, So Div, Sch Med, St Lucia, Qld 4067, Australia
[3] No Calif Canc Ctr, Fremont, CA USA
[4] Histopath, Sydney, NSW, Australia
关键词
D O I
10.1136/gut.2005.069674
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Interferon alpha (IFN-alpha) activated cellular signalling is negatively regulated by inhibitory factors, including the suppressor of cytokine signalling (SOCS) family. The effects of host factors such as obesity on hepatic expression of these inhibitory factors in subjects with chronic hepatitis C virus (HCV) are unknown. Objectives: To assess the independent effects of obesity, insulin resistance, and steatosis on response to IFN-alpha therapy and to determine hepatic expression of factors inhibiting IFN-alpha signalling in obese and nonobese subjects with chronic HCV. Methods: A total of 145 subjects were analysed to determine host factors associated with non-response to antiviral therapy. Treatment comprised IFN-alpha or peginterferon alpha, either alone or in combination with ribavirin. In a separate cohort of 73 patients, real time-polymerase chain reaction was performed to analyse hepatic mRNA expression. Immunohistochemistry for SOCS-3 was performed on liver biopsy samples from 38 patients with viral genotype 1 who had received antiviral treatment. Results: Non-response (NR) to treatment occurred in 55% of patients with HCV genotypes 1 or 4 and 22% with genotypes 2 or 3. Factors independently associated with NR were viral genotype 1/4 (p < 0.001), cirrhosis on pretreatment biopsy (p = 0.025), and body mass index >= 30 kg/m(2) (p = 0.010). Obese subjects with viral genotype 1 had increased hepatic mRNA expression of phosphoenolpyruvate carboxy kinase (p = 0.01) and SOCS-3 (p = 0.047), in comparison with lean subjects. Following multivariate analysis, SOCS-3 mRNA expression remained independently associated with obesity (p = 0.023). SOCS-3 immunoreactivity was significantly increased in obesity (p = 0.013) and in non-responders compared with responders (p = 0.014). Conclusions: In patients with chronic HCV viral genotype 1, increased expression of factors that inhibit interferon signalling may be one mechanism by which obesity reduces the biological response to IFN-alpha.
引用
收藏
页码:529 / 535
页数:7
相关论文
共 51 条
  • [1] Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors
    Akuta, N
    Suzuki, F
    Tsubota, A
    Suzuki, Y
    Someya, T
    Kobayashi, M
    Saitoh, S
    Arase, Y
    Ikeda, K
    Kumada, H
    [J]. JOURNAL OF HEPATOLOGY, 2002, 37 (06) : 831 - 836
  • [2] BANNER BF, 1995, MODERN PATHOL, V8, P232
  • [3] Novel concepts in insulin regulation of hepatic gluconeogenesis
    Barthel, A
    Schmoll, D
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 285 (04): : E685 - E692
  • [4] Effect of combined interferon-α induction therapy and ribavirin on chronic hepatitis C virus infection:: a randomized multicentre study
    Bjoro, K
    Bell, H
    Hellum, KB
    Skaug, K
    Raknerud, N
    Sandvei, P
    Doskeland, B
    Mæland, A
    Lund-Tonnesen, S
    Myrvang, B
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (02) : 226 - 232
  • [5] IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3
    Bode, JG
    Ludwig, S
    Ehrhardt, C
    Erhardt, A
    Albrecht, U
    Schaper, F
    Heinrich, PC
    Häussinger, D
    [J]. FASEB JOURNAL, 2003, 17 (01) : 488 - +
  • [6] High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C
    Bressler, BL
    Guindi, M
    Tomlinson, G
    Heathcote, J
    [J]. HEPATOLOGY, 2003, 38 (03) : 639 - 644
  • [7] PREDICTION OF THE RESPONSE OF CHRONIC HEPATITIS-C TO INTERFERON-ALFA - A STATISTICAL-ANALYSIS OF PRETREATMENT VARIABLES
    CAMPS, J
    CRISOSTOMO, S
    GARCIAGRANERO, M
    RIEZUBOJ, JI
    CIVEIRA, MP
    PRIETO, J
    [J]. GUT, 1993, 34 (12) : 1714 - 1717
  • [8] STATs and gene regulation
    Darnell, JE
    [J]. SCIENCE, 1997, 277 (5332) : 1630 - 1635
  • [9] DISISCEGLIE AM, 2002, HEPATOLOGY, V36, pS121
  • [10] Dumoulin FL, 2001, J HUMAN VIROL, V4, P195